LFCR.NASDAQLifecore Biomedical, INC \de\
10-Q: Lifecore Biomedical Reports Q1 2024 Results: Revenue Growth Offset by Margin Pressure and Net Loss
Sentiment:
Quarterly Report
Lifecore Biomedical's first quarter of fiscal year 2024 saw a revenue increase driven by CDMO growth, but was impacted by lower gross profit margins and a net loss.
Delay expectedThe company has accrued approximately $0.2 million in monetary penalties under the Registration Rights Agreement due to the delinquent filing of the company's annual and quarterly reports with the SEC.
Worse than expectedThe company's gross profit margin decreased significantly to 11.1% from 25.2%, indicating a worse than expected performance.The company reported a net loss of $10.754 million, which is worse than the prior year's net loss of $10.966 million when considering the increase in revenue.
Summary
- Lifecore Biomedical reported a net loss of $10.754 million for the quarter ended August 27, 2023, compared to a net loss of $10.966 million for the same period last year.
- Total revenue increased to $24.522 million, up from $23.724 million in the prior year, driven by a $3.3 million increase in contract development and manufacturing organization (CDMO) revenue.
- HA manufacturing revenue decreased by $2.5 million due to the timing of shipments.
- Gross profit decreased to $2.728 million from $5.979 million, with gross profit margin dropping to 11.1% from 25.2% due to an unfavorable sales mix and lower development revenues.
- Operating expenses increased to $11.342 million from $9.253 million, primarily due to higher selling, general, and administrative expenses.
- The company had $8.642 million in cash at the end of the quarter, a decrease of $10.449 million from the previous quarter.
- The company has a term loan credit facility with Alcon for $142.3 million and a revolving credit facility with BMO Harris Bank with a maximum of $40 million.
Sentiment
Score: 4
Explanation: The document presents a mixed picture with revenue growth offset by significant margin compression and a net loss. The presence of material weaknesses in internal controls and an SEC subpoena further dampen the sentiment. While there are some positive developments, the overall tone is cautious and concerning.
Positives
- Total revenue increased by 3% year-over-year, driven by growth in the CDMO segment.
- CDMO revenue increased by $3.3 million due to increased demand.
- The company secured a $142.3 million term loan credit facility with Alcon, refinancing previous debt.
- The company has a revolving credit facility with BMO Harris Bank with a maximum of $40 million.
Negatives
- The company reported a net loss of $10.754 million for the quarter.
- Gross profit decreased by 54% to $2.728 million due to an unfavorable sales mix.
- Gross profit margin decreased significantly to 11.1% from 25.2%.
- Operating expenses increased by 23% to $11.342 million.
- The company's cash balance decreased by $10.449 million to $8.642 million.
- HA manufacturing revenue decreased by $2.5 million due to the timing of shipments.
Risks
- The company's financial results are subject to fluctuations due to product mix, customer mix, and manufacturing costs.
- The company's debt obligations could impact its financial flexibility.
- The company's reliance on a few key customers poses a concentration risk.
- The company has identified material weaknesses in its internal control over financial reporting.
- The company is subject to legal proceedings and claims in the ordinary course of business.
- The company is responding to an SEC subpoena related to a prior restatement.
Future Outlook
The company believes that its cash from operations, along with existing cash and availability under its Revolving Credit Facility will be sufficient to finance its operational and capital requirements for at least the next twelve months.
Management Comments
- Management is committed to remediating the control deficiencies.
- Management believes that the claims in the class action complaint are without merit and intends to vigorously defend against them.
Industry Context
Lifecore operates in the contract development and manufacturing organization (CDMO) sector, which is experiencing growth due to increased outsourcing by pharmaceutical and biotechnology companies. The company's focus on sterile injectables and hyaluronic acid (HA) positions it in a niche market with specific expertise requirements.
Comparison to Industry Standards
- While specific competitor data is not provided in the document, the decrease in gross profit margin to 11.1% suggests potential underperformance compared to industry benchmarks for CDMOs, which often aim for margins in the 20-40% range.
- Companies like Catalent and Lonza, which are major players in the CDMO space, typically report higher gross profit margins due to their scale and diversified service offerings.
- The company's reliance on a few key customers and the related party nature of its debt with Alcon may be viewed as a risk compared to more diversified CDMOs.
- The company's ongoing efforts to remediate internal control weaknesses are critical for maintaining investor confidence and aligning with industry best practices.
Legal Proceedings
- The company is involved in various legal proceedings and claims in the ordinary course of business.
- On February 16, 2024, the Chicago Regional Office of the SEC issued a subpoena to the Company seeking documents and information concerning the Restatement.
- On July 29, 2024, a putative class action complaint was filed on behalf of shareholders of the Company in the United States District Court of Minnesota against the Company and certain of its named executive officers.
Related Party Transactions
- The company has significant related party transactions with Alcon, including a term loan credit facility, equipment sale and leaseback agreements, and a contract manufacturing agreement.
- The company has reflected the related party balances on the face of its financial statements beginning in the period which Alcon became a related party, which was as of May 22, 2023.
Stakeholder Impact
- Shareholders are negatively impacted by the net loss and the decrease in gross profit margin.
- Employees may be impacted by the strategic reduction of the company's workforce.
- Customers may be impacted by the company's ability to meet its obligations under the Amended and Restated CMA.
- Creditors are impacted by the company's debt obligations and the Assignment for the Benefit of Creditors.
Next Steps
- The company is in the process of determining a plan for the remediation of the material weaknesses in internal control over financial reporting.
- The company plans to implement new and enhanced controls and procedures responsive to its risk assessment.
- The company will continue to evaluate operating effectiveness and monitor improvements to its internal control over financial reporting.
Key Dates
| Date | Description |
|---|---|
| 2019-05-27 | Date related to asset write-off costs. |
| 2022-05-30 | Comparative period start date for financial data. |
| 2022-06-02 | Date of the BreatheWay Asset Purchase Agreement. |
| 2022-08-28 | Comparative period end date for financial data. |
| 2023-01-09 | Date of issuance of Series A Convertible Preferred Stock. |
| 2023-02-07 | Date of disposition of Yucatan Foods. |
| 2023-04-06 | Date of disposition of O Olive Oil and Vinegar. |
| 2023-05-22 | Date of the Term Loan Credit Facility and Revolving Credit Facility agreements. |
| 2023-05-28 | Prior quarter end date for comparative balance sheet data. |
| 2023-05-29 | Start date for current period financial data. |
| 2023-08-27 | End date for current period financial data. |
| 2023-09-19 | Date of cash payment from a settlement agreement. |
| 2023-09-28 | Date of a cash payment related to the O Olive sale. |
| 2023-12-11 | Date of a cash payment related to the O Olive sale. |
| 2023-12-22 | Date of the Amended Supply Agreement and receipt of working capital deposit. |
| 2023-12-31 | Date of the Credit Agreement Amendments and Amended and Restated Contract Manufacturing Agreement. |
| 2024-01-12 | Date of landlord complaints for past due rent. |
| 2024-02-16 | Date of SEC subpoena. |
| 2024-02-22 | Date of a cash payment related to the O Olive sale. |
| 2024-02-29 | Date related to a landlord complaint. |
| 2024-03-14 | Date of amendment to the Amended Supply Agreement. |
| 2024-05-02 | Date of amendment to the Amended and Restated CMA. |
| 2024-05-10 | Date of the Seventh Amendment to the ABL Loan Agreement. |
| 2024-05-15 | Date of the Assignment for the Benefit of Creditors. |
| 2024-05-22 | Maturity date of the Term Loan Credit Facility. |
| 2024-05-26 | Date related to a scenario forecast. |
| 2024-05-27 | Date related to a scenario forecast. |
| 2024-06-28 | Date of Shareholder Cooperation Agreements. |
| 2024-07-08 | Date of the Workforce Reduction Plan. |
| 2024-07-29 | Date of the Class Action Complaint. |
| 2024-08-09 | Date of the Amended Lease Agreement. |
| 2024-08-25 | Date related to a scenario forecast. |
Keywords
CDMO, HA manufacturing, contract manufacturing, sterile injectables, pharmaceutical products, sodium hyaluronate, financial results, debt, revenue, gross profit, net loss, operating expenses, internal controls, restructuring, Alcon, BMO Harris Bank
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.